Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of US $202 mn in the US
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Subscribe To Our Newsletter & Stay Updated